Ambev S.A. (NYSE: ABEV) American Depositary Receipts (ADRs) advanced 3.46% on Wednesday, closing at $2.99, as a broad rally in Brazilian equities lifted the stock. The move was primarily driven by a 2.83% gain in the Ibovespa index and a 0.57% appreciation of the Brazilian real against the U.S. dollar, rather than any company-specific news.
The ADR's five-session winning streak has brought its total gain to 3.8%. Trading volume reached 27.25 million shares, though this was 23% below the 10-day average, suggesting the move was part of a broader market rerating rather than a surge of investor interest in Ambev specifically.
Market Context
The Ibovespa closed at 185,205.09 points, up 3.05%, with trading volume of R$40.86 billion, surpassing the daily average of R$32 billion for the year. Analysts attributed the rally to strong foreign buying interest, with Marco Tulli Siqueira of Necton/BTG Pactual noting "foreign flow on the buy side."
The Brazilian real's strength against the dollar also contributed to the ADR's gains, as a stronger local currency increases the dollar value of Ambev's Brazilian earnings.
Fundamental Strength
Ambev reported solid second-quarter results, with organic revenue growing 6.1% to R$20.15 billion. Normalized EBITDA rose 8.9%, and the margin expanded by 80 basis points to 31.6%. Normalized profit jumped 23.3% to R$3.49 billion.
Brazilian beer volume increased 5.0%, with revenue up 8.9% and normalized EBITDA climbing 12.8%, achieving a segment margin of 33.5%. However, non-alcoholic volume in Brazil fell 4.4%, and Latin America South and Canada saw declines of 2.9% and 1.8%, respectively. Central America and the Caribbean posted a 5.4% increase.
Cost Pressures
Cash costs per hectoliter in Brazil rose 4.5%, slightly outpacing the 4.4% increase in revenue per hectoliter, highlighting ongoing cost pressures. Ambev maintained its full-year cost growth forecast of 4.5% to 7.5%.
Despite these challenges, cash generation improved significantly, with operating cash flow up 54.5% to R$4.71 billion. As of July 30, the company had distributed approximately R$5.9 billion to shareholders, covering about 95% of its declared buyback program.
Analyst Sentiment
Wall Street remains cautious on Ambev, with a consensus rating of "Hold" from 11 analysts. The average 12-month price target of $3.34 implies just 11.7% upside from Wednesday's close. UBS's target of $2.85 sits 4.7% below the current price.
Analyst targets range from a low of $2.60 to a high of $4.00, reflecting divergent views on the company's growth prospects amid Brazil's economic volatility.
Outlook
Investors will watch for continued momentum in Brazilian markets, with attention on foreign investment flows, the real's trajectory, and political developments. Ambev's next scheduled cash distribution is a R$1.9 billion interest-on-capital payout on October 6.
Key risks include a reversal in Brazilian capital flows, which could erase Wednesday's gains, and rising commodity prices that could push costs higher. Weaker volumes in other regions might also offset Brazil's beer sales growth.
